My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 490

    1.

    Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.

    Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML.

    Diabetes. 2002 May;51(5):1461-9.PMID: 11978643 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.

    Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X.

    Diabetologia. 1999 Nov;42(11):1324-31.PMID: 10550416 [PubMed - indexed for MEDLINE]Related articles

    3.

    KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.

    Kim KR, Rhee SD, Kim HY, Jung WH, Yang SD, Kim SS, Ahn JH, Cheon HG.

    Eur J Pharmacol. 2005 Jul 25;518(1):63-70.PMID: 16106524 [PubMed - indexed for MEDLINE]Related articles

    4.

    Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

    Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA.

    Diabetes. 2003 Mar;52(3):741-50.PMID: 12606516 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.

    Someya Y, Tahara A, Nakano R, Matsuyama-Yokono A, Nagase I, Fukunaga Y, Takasu T, Hayakawa M, Shibasaki M.

    Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):209-17. Epub 2008 Apr 9.PMID: 18398600 [PubMed - indexed for MEDLINE]Related articles

    6.

    Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.

    Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE, Wang PR.

    J Pharmacol Exp Ther. 2005 Nov;315(2):688-95. Epub 2005 Jul 18.PMID: 16027230 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.

    Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Tanaka I.

    Metabolism. 2003 Jan;52(1):81-6.PMID: 12524666 [PubMed - indexed for MEDLINE]Related articles

    8.

    Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice.

    Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M.

    Pharmacology. 2009;83(3):177-87. Epub 2009 Jan 29.PMID: 19176982 [PubMed - indexed for MEDLINE]Related articles

    9.

    7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.

    Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Shinoda M, Saeki T, Tanaka I.

    J Pharmacol Exp Ther. 2006 Dec;319(3):1253-7. Epub 2006 Sep 15.PMID: 16980568 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats.

    Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, Tanaka I.

    J Pharmacol Exp Ther. 2004 Aug;310(2):614-9. Epub 2004 Mar 23.PMID: 15039452 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.

    O'Harte FP, Mooney MH, Kelly CM, McKillop AM, Flatt PR.

    Regul Pept. 2001 Jan 12;96(3):95-104.PMID: 11111014 [PubMed - indexed for MEDLINE]Related articles

    12.

    Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

    Holst JJ, Deacon CF.

    Diabetes. 1998 Nov;47(11):1663-70. Review.PMID: 9792533 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.

    Reimer MK, Holst JJ, Ahrén B.

    Eur J Endocrinol. 2002 May;146(5):717-27.PMID: 11980629 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

    Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.

    Clin Ther. 2006 Jan;28(1):55-72.PMID: 16490580 [PubMed - indexed for MEDLINE]Related articles

    15.

    Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.

    Ahrén B, Holst JJ, Mårtensson H, Balkan B.

    Eur J Pharmacol. 2000 Sep 15;404(1-2):239-45.PMID: 10980284 [PubMed - indexed for MEDLINE]Related articles

    16.

    Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.

    Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H.

    Eur J Pharmacol. 2008 Jul 7;588(2-3):325-32. Epub 2008 Apr 10.PMID: 18499100 [PubMed - indexed for MEDLINE]Related articles

    17.

    Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.

    Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ.

    J Endocrinol. 2002 Feb;172(2):355-62.PMID: 11834453 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.

    Wargent E, Stocker C, Augstein P, Heinke P, Meyer A, Hoffmann T, Subramanian A, Sennitt MV, Demuth HU, Arch JR, Cawthorne MA.

    Diabetes Obes Metab. 2005 Mar;7(2):170-81.PMID: 15715890 [PubMed - indexed for MEDLINE]Related articles

    19.

    Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.

    Lugari R, Dei Cas A, Ugolotti D, Barilli AL, Camellini C, Ganzerla GC, Luciani A, Salerni B, Mittenperger F, Nodari S, Gnudi A, Zandomeneghi R.

    Horm Metab Res. 2004 Feb;36(2):111-5.PMID: 15002062 [PubMed - indexed for MEDLINE]Related articles

    20.

    Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study.

    Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA.

    Diabetes. 2002 Sep;51(9):2677-83.PMID: 12196458 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity